This website is intended for healthcare professionals only.
ADVANCING mPaCa CARE: CHARACTERIZING LONG-TERM SURVIVORS
Prof. Davide Melisi, MD, PhD (Italie), Associate Professor of Medical Oncology
Digestive Molecular Clinical Oncology Research Unit, Head University of Verona
Division of Medical Oncology
Dr. Hiroshi Imaoka, MD (japon), Assistant Chief, Dept of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East (Kashiwa-shi, Chiba, Japan)
This webinar looks at long-term survival in metastatic pancreatic cancer (mPaCa), and more specifically, the baseline characteristics associated with this survival. It highlights the predictors of long-term survival that have been identified in clinical trials, both in the 1st and 2nd line setting. It shows how only some of these factors are predictive in the real-world setting, and that more research is needed in this area. Two clinical cases of long-term survivors treated with Nal-IRI + 5-FU/LV are presented by the speakers.
Key points covered
This webinar looks at long-term survival in mPaCA, and more specifically the identification of baseline characteristics:
in the 1L setting – an example with gemcitabine + nab-paclitaxel
in the 2L setting – with nal-IRI + 5-FU/LV (NAPOLI-1)
in the real-world setting – with both real-world studies and patient cases
Both Prof Melisi and Dr Imaoka cover cases from their own experience on long-term survival with nal-IRI + 5-FU/LV.
Webinar Replay
Featured Speakers
Prof. Davide Melisi
Davide Melisi is an Associate Professor of Medical Oncology
at the University of Verona and Director of the Experimental
Therapies in Oncology Unit at the University Hospital of Verona.
Prof. Melisi has dedicated his career to oncology research. He’s
worked on basic, translational, and clinical research focusing
on gastrointestinal neoplasms.
In 2011, he received a prestigious grant from the Italian
Association for Cancer Research, establishing the Molecular
Clinical Oncology Research Unit for the Digestive System. At
the University of Verona, he actively contributes to the Pancreas
Institute, participates in Center for early-phase development of
experimental oncology therapies, and teaches medical oncology.
He’s received various prestigious awards, such as the “Prof.
Piero Trivella” 2003 award, “Marion D. Edwards» 2007 award
in hepatic oncology, and the “Gaetano Salvatore” Culture Award
in 2023.
Dr. Hiroshi Imaoka
Dr. Hiroshi Imaoka is an assistant chief of department of
hepatobiliary and pancreatic oncology at National Cancer Center
Hospital East in Japan. He received M.D. degree from Kobe
University School of Medicine in 2000.
He was a chief of department of gastroenterology at Aichi cancer
center hospital from 2011 to 2016, then he moved to National
Cancer Center Hospital East. He was appointed an assistant
chief of department of hepatobiliary and pancreatic oncology at
National Cancer Center Hospital East in 2019.
He specializes in chemotherapy and endoscopic treatment for
pancreatic cancer, biliary tract cancer, and liver cancer. He
also participates in various clinical trials as an investigator. In
addition to being active in medical societies within Japan, he is
also a member of international congresses such as ASCO and
ESMO.
